Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 15, 2014 - Issue 7
Submit an article Journal homepage
692
Views
14
CrossRef citations to date
0
Altmetric
Drug Evaluations

Teriflunomide: a novel oral treatment for relapsing multiple sclerosis

Arianna SartoriUniversity of Trieste, Ospedale di Cattinara - Azienda Ospedaliero-Universitaria Ospedali Riuniti, Department of Medical, Surgical and Health Sciences (Neurology), 447 Strada di Fiume, 34149 Trieste, Italy+39 040 399 4321; +39 040 910 861; [email protected]
, MD,
Dawn CarleUniversity of Ottawa, Department of Medicine (Neurology), 501 Smyth Road, Ottawa, ON K1H 8L6, Canada
, RN BScN &
Mark S FreedmanUniversity of Ottawa, Department of Medicine (Neurology), 501 Smyth Road, Ottawa, ON K1H 8L6, Canada
, MSc MD FANA FAAN FRCPC
Pages 1019-1027 | Published online: 17 Apr 2014

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Marieke Krol, Gert de Voer & Ulrike Osowski. (2017) Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis. Patient Preference and Adherence 11, pages 1189-1196.
Read now
Fabiana Auricchio, Cristina Scavone, Daniela Cimmaruta, Gabriella Di Mauro, Annalisa Capuano, Liberata Sportiello & Concetta Rafaniello. (2017) Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opinion on Drug Safety 16:12, pages 1359-1371.
Read now
Athina Papadopoulou, Ludwig Kappos & Till Sprenger. (2015) Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety 14:5, pages 749-759.
Read now

Articles from other publishers (11)

Belén Valenzuela, Juan-José Pérez-Ruixo, Quentin Leirens, Sivi Ouwerkerk-Mahadevan & Italo Poggesi. (2021) Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis. Clinical Pharmacokinetics 60:9, pages 1239-1250.
Crossref
Miriam Fedičová, Marianna Vitková, Jarmila Szilasiová & Zuzana Gdovinová. (2020) Multiple sclerosis (MS) is autoimmune disorder affecting the central nervous system. Neurologie pro praxi 21:3, pages 203-208.
Crossref
Tezcan Guney, Todd A. Wenderski, Matthew W. Boudreau & Derek S. Tan. (2018) Synthesis of Benzannulated Medium-ring Lactams via a Tandem Oxidative Dearomatization-Ring Expansion Reaction. Chemistry - A European Journal 24:50, pages 13150-13157.
Crossref
N. V. Khachanova & T. V. Gorokhova. (2016) Extending the Potential of the Treatment of Multiple Sclerosis with a New Agent for Oral Use – Teriflunomide (Aubagio). Neuroscience and Behavioral Physiology 47:1, pages 112-116.
Crossref
Kyu Sik Shin, Jae Gun Park & Min Su Park. (2016) Reduction of Disease Activity in Patient with Relapsing-Remitting Multiple Sclerosis after Switching to Teriflunomide from Interferon Beta. Journal of the Korean Neurological Association 34:1, pages 77-79.
Crossref
Jens Ingwersen, Orhan Aktas & Hans-Peter Hartung. (2015) Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics 13:1, pages 47-57.
Crossref
Rebecca S. Farber & Ilana K. Sand. (2015) Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders 8:5, pages 212-232.
Crossref
Woojun KimManuella Edler ZandonáSu-Hyun KimHo Jin Kim. (2015) Oral Disease-Modifying Therapies for Multiple Sclerosis. Journal of Clinical Neurology 11:1, pages 9.
Crossref
N. V. Khachanova & T. V. Gorokhova. (2015) Widening of possibilities of treatment of multiple sclerosis with the novel oral drug teriflunomide (aubagio). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 115:2. Vyp. 2, pages 61.
Crossref
Zhong-Xiang Xie, Hong-Liang Zhang, Xiu-Juan Wu, Jie Zhu, Di-Hui Ma & Tao Jin. (2015) Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis. Mediators of Inflammation 2015, pages 1-20.
Crossref
Amit Bar-Or. (2014) Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. Experimental Neurology 262, pages 57-65.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.